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INTRODUCTION
In most countries, end-stage renal disease (ESRD) is increas-
ing (1, 2), with further increases in the future. Over the past
decades the treatment of patients with ESRD by dialysis or
transplantation has improved considerably. Nevertheless, nei-
ther form of renal replacement therapy (RRT) is thought to
be ideal because each modality has its specific advantages and
disadvantages. Although kidney transplantation is felt to offer
the best survival and quality of life, the majority of ESRD
patients at some time in their life are faced with choosing
between hemodialysis (HD) or peritoneal dialysis (PD) (3,
4). The best choice of dialytic modality in terms of patient
outcome has not been well established. The choice has there-
fore usually been made on the basis of the patient’s social needs
or modality availability; unless a medical contraindication
precludes the use of a specific modality. Since continuous am-
bulatory peritoneal dialysis (CAPD) was introduced in the
late 1970s, there have been several studies which compared
patient survival between HD and PD (5, 6). However, results
are conflicting. Both earlier and more recent studies have
shown inconsistent results for comparative mortality (4, 7-
11). Results appear to vary by country and, in some cases,
even within a country. All of these studies are observational,
and therefore inconsistent results may be due to unavoidable
and varying selection biases that are seen in nonrandomized
studies. To compare each treatment options it is necessary to
have as little bias as possible concerning baseline characteristics
affecting morbidity and mortality, such as age, comorbid con-
ditions and acceptance policies for renal transplantation.
Over the past decade, a number of large-scale studies have
examined the impact of dialysis modality on the survival of
individuals with ESRD (4, 12-14). However, little informa-
tion is available concerning any differential trends in mortality
among renal replacement therapy in Asian ESRD populations.
The purpose of this study was to investigate clinical charac-
teristics and any differential trends in mortality between HD
and PD, and between dialysis and renal transplantation in
Korean ESRD population. We further postulate that, consis-
tent with previous studies, the key segments are defined by
age, cause of ESRD, and baseline level of comorbidity. Our
specific goals were to identify key risk factors for which the
risk of death differs by renal replacement modality, and to
adjust mortality comparisons between HD and PD by strati-
fying on these factors. 
MATERIALS AND METHODS
Medical records of ESRD patients who began dialysis or
Young-Soo Song, Heesun Jung*, 
Jinyoung Shim*, Changkwon Oh
� , 
Gyu-Tae Shin*, Heungsoo Kim*
Department of Internal Medicine, Hallym University
College of Medicine, Seoul; Departments of 
Nephrology*, Surgery
� , Ajou University School of
Medicine, Suwon, Korea
Address for correspondence
Heungsoo Kim, M.D.
Department of Nephrology, Ajou University School of
Medicine, San-5 Woncheon-dong, Youngtong-gu,
Suwon 443-721, Korea 
Tel : +82.31-219-5130, Fax : +82.31-219-5137
E-mail : nephrohs@ajou.ac.kr
*Presented at the 55th meeting of the Korean Associa-
tion of Internal Medicine, Seoul, 2004.
81
J Korean Med Sci 2007; 22: 81-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Survival Analysis of Korean End-Stage Renal Disease Patients
According to Renal Replacement Therapy in a Single Center
This study was to investigate clinical characteristics and any differential trends in
survival among renal replacement therapy (hemodialysis [HD], peritoneal dialysis
[PD], and kidney transplantation [KT]) in Korean end-stage renal disease (ESRD)
population. We tried to analyze retrospectively the survival rate adjusted by risk fac-
tors and the relative risk stratified by key risk factors among 447 ESRD patients who
began dialysis or had a kidney transplant at Ajou University Hospital from 1994 to
2004. In adjusted Cox survival curves, the KT patients had the best survival rate,
and the HD patients had better survival than PD patients. The consistent trends in
different subgroups stratified by age and diabetes were as following: 1) The risk of
death for PD and HD was not proportional over time, 2) The relative risk of PD was
similar or lower than that of HD for the first 12 months, but it became higher at later
period. The significant predictors for mortality were age (over 55 yr), presence of
diabetes, cerebrovascular accident at ESRD onset, and more than one time of hos-
pitalization caused by malnutrition. Further large-scaled, multicenter-based com-
parative study is needed in Korean ESRD patients and more meticulous attention
is required in high-risk patients.
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had a kidney transplant at Ajou University Medical Center
from September 1994 to November 2004 were reviewed ret-
rospectively. This study was in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki. Of
these patients, those who maintained the same mode of RRT
more than 3 months were eligible for this study. In these pa-
tients, those who had not regular follow-up in either our cen-
ter or at local dialysis facilities were excluded. The patients
who had accompanying malignancy or life expectancy less
than 6 months at the beginning of RRT were excluded. The
patients, whose data on predialysis or pretransplatation comor-
bid conditions was not available, were also excluded. The
patients were divided into three groups by RRT modalities:
HD, PD, kidney transplant (KT) groups. The patients who
had KT at any time of ESRD were considered as KT group
and the periods undergoing dialysis were censored in this
group. The resulting study population included 447
patients: HD group (179 patients), PD group (165 patients)
and KT group (103 patients). Patient characteristics includ-
ing age, sex, causes of ESRD, comorbidity at the time of RRT
initiation (hypertension, cerebrovascular accident, ischemic
heart disease, congestive heart failure, liver disease), biochem-
ical markers (blood urea nitrogen, creatinine, calcium, total
protein, albumin, and total cholesterol), hemoglobin, hema-
tocrit and viral markers at the beginning of RRT were record-
ed. The comorbid conditions were defined as follow: Hyper-
tension: systolic blood pressure over 140 mmHg, diastolic
blood pressure over 90 mmHg, or the need for antihyper-
tensive medication; ischemic heart disease: history of prior coro-
nary artery disease, myocardial infarction, angioplasty, coro-
nary artery bypass graft; congestive heart failure: systolic ejec-
tion fraction below 40% in echocardiographic evaluation;
cerebrovascular accident, either hemorrhage or infarction: history
and neurologic deficit; liver disease: cirrhosis, B and C viral
hepatitis by biochemical or abdominal sonographic evalua-
tion. Baseline glomerular filtration rate was determined from
Cockcroft-Gault equation, which is based on serum creati-
nine, age, body weight and gender.
We tried to investigate the patient survival, technical sur-
vival, and morbidity during the course of RRT: the incidences
of cardiovascular complication (congestive heart failure, is-
chemic heart disease), infection, cerebrovascular accident,
malignancy, and protein-calorie malnutrition. In addition
to medical records, we tried to make a contact with patients
or patient’s family by phone call in cases of being cared at
local dialysis facility. We counted the incidences of de novo
development of congestive heart failure, ischemic heart dis-
ease, and cerebrovascular accident either hemorrhage or infarc-
tion. The incidence of infection including CAPD peritonitis
was counted only in cases requiring hospitalization. We de-
fined protein-calorie malnutrition by clinical discernment
(the patient with serum albumin is less than 3.5 g/dL and
being judged as malnourished by subjective global assess-
ment) and counted only in cases of requiring hospitalization.
Statistical analysis
Results are presented as mean±standard deviation (SD).
Baseline characteristics of each RRT patients were compared
using chi-square tests and analysis of variance (ANOVA). We
employed an as-treated model in assessing the association of
treatment modality and risk of death in patients with RRT.
Since an intention-to-treat modality is used to determine the
association between the specified dialysis modality chosen
at ESRD onset and subsequent mortality, irrespective of any
future changes in modality, patients are not censored even if
they change treatment modality during follow-up and patient
death is assigned to the initial treatment modality. On the
contrary, since an as-treated model is used to determine the
risk of death while being treated by a specified modality dur-
ing the follow-up period, patients are censored when they
switch from one modality to another.
Since preliminary analyses demonstrated that the impact
of RRT on mortality varied with time (p<0.05), thereby vio-
lating proportionality assumption of the Cox proportional
model, time-dependent Cox regression were used to identify
the significant prognostic factors affecting survival rate among
each patients group. In order to find independent factors,
demographic variables and covariates satisfying the signifi-
cant level (p<0.05) in univariate Cox regression analysis, were
analyzed in multivariate Cox regression analysis. Also, we com-
pared relative risk among RRT groups using interval Pois-
son regression, which were stratified for age and diabetes by
12-month interval.
The SPSS package version 12.0 statistic software was used.
A pvalue less than 0.05 was taken to indicate statistically sig-
nificant. 
Survival analysis
The Cox survival curve adjusted by age, gender, diabetes
and other risk factors analyzed to be significant in univariate
Cox regression was used to compare the survival rate among
groups. The patient’s cumulative survival duration was mea-
sured from the start of the first RRT to an end-point. We
considered the end-point as follow: death from any causes,
change to other modality of RRT, and at the end of this study
whichever came first. In KT group, the patient’s cumulative
survival duration was measured from the date of transplanta-
tion to end-points. After initially fulfilling the selection cri-
teria, patients were not excluded. Instead, we chose a censor-
based analysis, in which the patients were censored on chang-
ing to other modality of RRT, or reaching final follow-up for
mortality analysis. 
The Kaplan-Meier analysis was used to compare the tech-
nical survival rate among groups. The duration of technical
survival was measured from the start of the RRT to the tech-
nical failure. In the HD group, a change to peritoneal dialy-
sis due to loss of hemodialysis access and cardiovascular orSurvival Analysis of Korean End-Stage Renal Disease Patients 83
hemodynamic cause was considered as technical failure. Also
in the PD group, the removal of intraperitoneal catheter from
any causes was considered technical failure. Those who had
died and were effective in the modality function were analyzed
as being technically alive.
RESULTS
Baseline characteristics of patients
The baseline characteristics are summarized in Table 1 for
447 eligible patients who began HD (n=179), PD (n=165)
or had a KT (n=103). The patients with KT were signifi-
cantly younger than those with dialysis (p< 0.05). Male sex
predominated significantly in KT patients. When censor-
ing was performed, mean follow-up time was 49.0±30.5
months (range 3-157 months). Fig. 1 illustrates the causative
disease for ESRD in each RRT modality. Compared with
dialysis patients, KT patients were more likely to have glo-
merulonephritis as a cause of ESRD (p<0.05). The distribu-
tion of causes of ESRD was similar between HD and PD.
The baseline level of serum creatinine and phosphorus were
significantly higher in KT patients than those of HD and
PD patient (Table 2). The viral antigen of hepatitis B was
more likely (p<0.05) to be positive in PD patients than that
in other two groups. Other biochemical markers and he-
matologic markers were not different significantly among
groups. 
The comorbid conditions at the beginning of RRT were
present in Table 1. Hypertension was the most common co-
morbidity in all RRT modalities. The prevalence of ischemic
heart disease was similar between HD and PD group, which
was significantly higher than that in KT group. The preva-
lence of cerebrovascular accident (CVA) in PD patients (9.1
%) was significantly higher than that in the other two groups
(HD 2.8%, RT 0%). The distribution of other comorbid
conditions did not differ significantly among RRT modali-
ties. 
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Fig. 1. The causes of end-stage renal disease (ESRD) in each re-
nal replacement therapy group. The distribution of causes of ES-
RD was similar between patients on hemodialysis and patients on
peritoneal dialysis. Compared with dialysis patients, renal trans-
plant patients were more likely (p<0.05) to have glomerulonephri-
tis and less likely (p<0.05) to have diabetes as a cause of ESRD.
CGN, chronic glomerulonephritis; DM, diabetes mellitus.
Hypertension
Others
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CGN
Characteristic HD
(n=179)
PD
(n=165)
KT
(n=103)
Sex (M/F)  95/84 76/89 66/37*
Age (yr) 54±13 54±14 36±11
�
Comorbidity
Diabetes 104 (58.1%) 84 (50.9%) 8 (7.8%)
�
Hypertension
a 146 (81.6%) 148 (89.7%)
� 87 (84.5%)
Ischemic heart disease
b 15 (8.4%) 17 (10.3%) 0 (0%)
�
Congestive heart failure
c 11 (6.1%) 11 (6.7%) 0 (0%)
Left ventricular hypertrophy
d 57 (31.8%) 63 (38.2) 27 (26.2%)
Cerebrovascular accident
e 5 (2.8%) 15 (9.1%)
� 0 (%)
Liver disease
f 13 (7.3%) 15 (9.0%) 3 (2.9%)
BMI
g (kg/m
2) 22.0±3.4 22.2±2.8 21.7±2.7
Follow-up duration (months) 49.4±33.7 40.6±24.6
� 62.0±28.6
�
Table 1. Demographic data and comorbidity factors of end-stage
renal disease patients at the time of renal replacement therapy
initiation 
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation. 
a,
Systolic BP >140 mmHg or diastolic BP >90 mmHg, or medicated with
antihypertensive drug; 
b, A history of prior coronary artery disease, myo-
cardial infarction, angioplasty, coronary artery bypass graft; 
c, Defined
by ejection fraction below 40% in echocardiographic evaluation; 
d, Defined
by electrocardiographic or echocardiographic evaluation; 
e, Cerebral
infaction or hemorrhage, defined by old and recent history and neuro-
logic deficit; 
f, alcoholic cirrhosis, viral cirrhosis, B and C viral hepatitis;
gbody mass index.
*, p<0.05, the number of male was larger than female within KT group;
� , p<0.05, compared with HD and PD; 
� , p<0.05, compared with HD
and KT; 
�, p<0.05, compared with HD.
Laboratory values HD PD KT
Blood urea nitrogen (mg/dL) 96±35 95±37 98±33
Creatinine (mg/dL) 10.1±4.5 9.8±4.5 13.3±5.4*
Creatinine clearance  6.4±4.0 6.9±5.1 4.2±2.6
(mL/min/1.73 m
2)
Calcium (mg/dL) 7.4±1.1 7.7±1.0 7.4±1.3
Phosphorus (mg/dL) 6.5±2.1 6.1±2.0 7.3±2.3*
Calcium×phosphorus 47.3±2.1 47.1±1.9 55.3±2.3*
Total protein (g/dL) 6.1±0.9 6.1±0.8 6.0±0.8
Albumin (g/dL) 3.2±0.7 3.3±0.6 3.3±0.6
Total cholesterol (mg/dL) 197±69 187±64 189±70
Hemoglobin (g/dL) 7.6±1.9 7.9±1.7 7.4±1.7
Hematocrit (%) 22.5±5.5 23.4±5.0 21.9±5.2
HBs Ag positivity 6 (3.4%) 14 (8.5%)
� 1 (1.0%)
Anti-HCV positivity 6 (3.4%) 2 (1.2%) 1 (1.0%)
Table 2. Laboratory findings of end-stage renal disease patients
at the time of renal replacement therapy initiation 
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation.
*, p<0.05, compared with HD and PD; 
� , p<0.05, compared with HD and
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Morbidity during follow-up 
The de novo development of congestive heart failure in HD
patients was significantly higher, whereas CVA was more
likely (p<0.05) to occur in PD patients (Table 3). The inci-
dence of infection was significantly different among each mo-
dality, and highest in PD patients and lowest in HD patients.
PD patients were significantly prone to hospitalize because of
clinically relevant malnutrition than other patients (p<0.05). 
Technical survival 
The HD group showed significantly better outcomes in
terms of technical survival than the PD group (p<0.05). The
HD group showed slightly higher technical survival rate than
the KT group, but the difference was not significant. The
5-yr technical or graft survival rates of the HD, PD, and KT
groups were 97.5%, 72.8%, and 93.7%, respectively (data
not shown). 
Risk factors affecting patient survival
By univariate analyses, the factors affecting the patient sur-
vival were female, diabetes, age over 55 yr, more than one
time of hospitalization caused by malnutrition, serum crea-
tinine below 10 mg/dL, serum phosphorus below 6 mg/dL,
serum albumin below 3.2 g/dL, cerebrovascular accident and
congestive heart failure at the initiation of RRT (Table 4). The
independent predictors for mortality by multivariate analysis
were age, diabetes, cerebrovascular accident at the initiation
of RRT, and more than one time of hospitalization caused by
malnutrition (Table 5).
In each modality patients, the risk factor for death was in-
vestigated separately. Significant independent risk factors for
death in HD patients were age over 55 yr, diabetes, and albu-
min below 3.2 g/dL, whereas age over 55 yr, diabetes, cere-
brovascular accident at the initiation of RRT, and malnutri-
tion were significant independent risk factors in PD patients.
Patient age and diabetes were key risk factors in dialysis gro-
ups. Patient age was the only significant risk factor in KT
patients.
Patient survival by mode of RRT
During the follow-up, the overall patient mortality was
23.7% (106 cases). The cause of death in each RRT patients
was shown in Fig. 2. The most common cause of death was
cardiac disease in HD group. Infection and cachexia were the
two leading causes of death in PD group. The adjusted Cox
survival curves were shown in Fig. 3. The patient cumulative
survival was significantly different among the three modali-
ties. The KT group showed the highest survival rate and the
PD group the lowest survival rate (p<0.05).
Fig. 4 shows the relative risk of death among RRT groups
in overall patients by 12-month interval. The relative risk
Morbidity HD (n=179) PD (n=165) KT (n=103)
Ischemic heart disease
a 7.9% 6.8% 2.9%
Congestive heart failure
b 10.1%* 3.1% 2.0%
Cerebrovascular accident
c 5.6% 10.5%
� 1.0%
Infection
d 10.7% 34.6%
� 19.6%
�
Malignancy
e 1.7% 1.2% 3.9%
Malnutrition
f 1.7% 10.5%
� 0%
Table 3. Development of morbidity during follow-up
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation. 
a,
Evidenced by coronary angiography with or without coronary angioplas-
ty, myocardial infarction, coronary artery bypass graft; 
b, Defined by sys-
tolic ejection fraction below 40% in echcardiographic evaluation; 
c, Cere-
bral infarction or hemorrhage, defined by computed tomography; 
d, Hos-
pitalization due to infection including peritonitis in PD group; 
e, Hospital-
ization due to clinically defined malnutrition over 1 time.
*, p<0.05, compared with PD, KT; 
� , p<0.05, compared with KT; 
� , p<0.05,
compared with PD, KT; 
�, p<0.05, compared with HD.
Covariate Odds ratio p value
Confidence
interval
Female 1.52 0.03 1.04-2.23
Age over 55 yr 5.54 0.00 3.53-8.69
Diabetes 6.42 0.00 4.10-10.03
Malnutrition* 4.69 0.00 2.60-8.44
Serum Cr <10 mg/dL 2.96 0.00 1.86-4.72
Phosphorus <6 mg/dL 1.88 0.00 1.26-2.80
Serum albumin <3.2 g/dL 1.65 0.01 1.11-2.44
CVA history
� 3.31 0.00 1.59-6.88
CHF
� 2.06 0.05 1.00-4.25
Table 4. Factors affecting patient’s death by univariate analysis
of variates
All the values are examined at the time of RRT initiation except malnu-
trition.
*, Hospitalization due to clinically defined malnutrition (serum albumin
<3.5 g/dL and by subjective global assessment) over 1 time; 
� , Cerebro-
vascular accident; cerebral infarction or hemorrhage, defined by old and
recent history and neurologic deficit at the time of renal replacement
therapy initiation; 
� , Congestive heart failure; defined by systolic ejection
fraction below 40% in echocardiographic evaluation at the time of renal
replacement therapy initiation. 
Covariate Odds ratio p value
Confidence
interval
Age over 55 yr 3.756 0.000 2.097-6.726
Diabetes 3.356 0.000 1.924-5.854
Malnutrition* 2.371 0.008 1.247-4.507
CVA history
� 2.146 0.049 1.004-4.587
Table 5. Independent predictors of death by time dependent
Cox regression
*, Hospitalization due to clinically defined malnutrition (serum albumin
<3.5 g/dL and by subjective global assessment) over 1 time; 
� , Cere-
brovascular accident; cerebral infarction or hemorrhage, defined by old
and recent history and neurologic deficit at the time of renal replacement
therapy initiation.among RRT was not proportional over time, especially bet-
ween HD and PD. The relative risk of HD was similar or
higher than that of PD group for the first 12 months, but it
became lower than that of PD at later period. Fig. 5 shows
the relative risk of death among RRT groups stratified by
key factors (age and diabetes) by 12-month interval. Over
entire 4 strata, the relative risks of HD became lower than
those of PD at later period, though the levels of relative risks
for HD at initial periods were different each other. The KT
group showed lower relative risk than the other groups across
entire 4 strata as shown in Fig. 5.
DISCUSSION
There has been controversy regarding which renal replace-
ment modality provides the greatest patient survival. In this
study, we found better survival rate as well as lower morbidity
during follow-up in KT group compared with dialysis groups
(Table 3, Fig. 3). This study that compared the outcome am-
ong patients who received transplants with that among pa-
tients on dialysis seemed to be biased in favor of the former
group, because high-risk patients on dialysis who were not
candidates for transplantation were included. Another rea-
son is that the KT patients were significantly younger than
other patients and that, in fact, the age was found to be key
risk factor for death in all RRT patients. To overcome this
concern, we repeated the Cox survival analysis adjusted by
known key risk factors, including only those measures of
variables that could be recorded with accuracy. We repeated
our analyses with and without adjustment, which again yield-
ed results similar to the original finding that KT had better
survival rate.
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Fig. 3. Adjusted Cox survival curves according to renal replace-
ment therapy. It was adjusted for age, diabetes, more than one
time of hospitalization caused by malnutrition, cerebrovascular
accident at the initiation of renal replacement therapy (RRT), which
were analyzed to be independent predictors of death by time de-
pendent Cox regression. The patient’s survival rates were signifi-
cantly different among groups. The KT group showed the best
survival rate over the entire follow-up period and the PD group
showed the lowest survival rate. KT, kidney transplantation; HD,
hemodialysis; PD, peritoneal dialysis.
KT
n=103
PD
n=165
HD
n=179
01 02 0 3 04 05 0 6 0
Per cent
Fig. 2. The causes of death according to modality of renal replace-
ment therapy (RRT). The proportions from each RRT represent
the mortality ratios within relevant RRT group and the each seg-
ment within RRT represents the individual cause of death. While
the proportion of cardiac cause in hemodialysis was higher than
that of the other two groups significantly (p<0.05), the proportions
of infection and cachexia in peritoneal dialysis were higher than
that of the other two groups significantly (p<0.05). CVA, cerebrova-
scular accident. *: p<0.05, compared with PD and with KT; 
� : p<
0.05, compared with HD and with RT; 
� : p<0.05, compared with KT.
HD, hemodialysis; PD, peritoneal dialysis; KT, kidney transplantation.
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Fig. 4. Relative risk of death among renal replacement of therapy
groups in overall patients by 12-month interval. Each relative risk
is plotted against the endpoint of the follow-up interval to which it
pertains. The relative risk among renal replacement therapy was
not proportional over time, especially between hemodialysis (HD)
and peritoneal dialysis (PD). The relative risk of HD was similar or
higher than that of PD group for the first 12 months, but it became
lower than that of PD at later period.Earlier reports on patient outcome of PD and HD gave
conflicting results, ranging from favorable for HD over no
difference to favorable for PD (4, 8, 10, 11, 13, 16-23). As
pointed out by Port et al. (21), correct interpretation of these
studies is difficult because they differ in many aspects, such
as type of statistical analysis (with or without correction for
comorbidity, and presence of different factors of comorbidity),
use of single center versus multicenter data, inclusion of inci-
dent or prevalent patients, and duration of follow-up. In our
analysis, the outcomes of the patients who began and remain
on their initial therapy from September 1994 to November
2004 were worse for PD Patients compared with HD or KT
patients. Although the patient’s outcomes itself in our study
were somewhat different to those of other studies, by the dif-
ferences in ethnics, methodology and body mass index, the
survival trends were similar (15, 24, 25).
The mechanism through which PD may contribute to this
increased mortality risk in this study group, especially in later
treatment period, is unclear. But these results could be par-
tially explained by the deterioration of the quality of the peri-
toneal membrane and by the loss of residual renal function
over time. The loss of residual renal function, which was re-
ported as independent risk factor for mortality (26), might
give an additional impact on survival of PD patients at later
treatment period in this group, although not being evaluat-
ed in this study (27). In addition to possible harmful effect
caused by changes in peritoneal membrane, it is suggested
that the rising mortality rate for PD patients later in the fol-
low-up may be attributed to the fact that patients on PD have
less chance to see their health care providers (an average of
one visit a month) compared with patients on HD (an aver-
age of three visits a week). Consequently, patients on PD have
more chance for delayed recognition and treatment of life-threat-
ening complications than do patients on HD (14). The like-
lihood of developing infections such as peritonitis especially
refractory or fungal peritonitis may add to the mortality risk
of PD patients. And these infectious complications, which
were the main cause of death for PD patient in this study,
may contribute the development of malnutrition leading to
cachexia, which was another main cause of death. Neverthe-
less, outcomes may be caused by other effects rather than by
modality effect itself.
Several studies have suggested that PD has early survival
benefit over HD for 2-3 yr (11, 14) due in part to a better
preservation of residual renal function during the early peri-
od with PD (27, 28), a higher incidence of late referral with
HD, and early complications associated with vascular access
in HD (25). But such an early beneficial effect on survival of
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Fig. 5. Relative risk of death among renal replacement of therapy groups stratified by key risk factors (age and diabetes) by 12-month inter-
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Relative risk of PD=1PD did not persisted in our study (Fig. 3).
We tried to find the prognostic factor affecting patient’s
survival at the time of RRT initiation and during the follow-
up, but we could not evaluate the compliance of patients for
each modality, severity of each comorbid illness, impact on
late referral, the degree of blood pressure control and anemia
correction, monitoring of parameters for cardiovascular dis-
ease and nutritional status, smoking status, monitoring of
dialysis adequacy, residual renal function, the effect of dialyzer
reuse system and different PD solution in dialysis groups.
Although the extent to which those parameters would affect
the survival rate systematically by RRT modality is unclear,
we consider those parameters could have some impact on the
survival of ESRD patients.
Unlike other studies, we evaluated the morbidity during
follow-up. As mentioned above, the development of conges-
tive heart failure in HD group was higher than that of the
other groups significantly (p<0.05). This probably might
reflect the hemodynamic stress on HD group. The higher
development of cerebrovascular accident in PD group was
partially due to the predisposing condition, namely higher
incidence of cerebrovascular accident at the time of dialysis
initiation or due to the accelerated atherosclerosis, which is
frequently found in ESRD patients, especially in PD patients
as suggested by several studies (29, 30). In our study, the in-
cidence of malnutrition requiring for hospitalization in PD
group was higher than that of the other groups and malnutri-
tion-associated cachexia as a cause of death in this group was
higher than that of the other group. This was agreed with the
studies that protein-calorie malnutrition was highly preva-
lent and main cause for mortality in PD patients (31-33). 
Recently, Vonesh et al. (25) reported that despite metho-
dological differences of several studies, there are some very
important trends. First, mortality rates for PD and HD were
not proportional over time (12, 14). The risk of death for PD
is generally lower during the first year or two of dialysis. There-
after, the risk of death is either comparable between the two
modalities or higher in patients on PD. Consistent with this
finding, the relative risk of PD was similar or lower than that
of HD group for the first 12 months, but it became higher
than that of HD later period in this study (Fig. 4). A second
trend common to these studies was the identification of sig-
nificant interactions between various risk factors and treat-
ment modality. Ganesh et al. (34) and Stack et al. (35) also
identified important interactions between comorbidity and
dialysis modality that had not been accounted for in previous
studies. The inclusion of such key interactions is necessary if
an accurate assessment of mortality differences between PD
and HD is to be made. For example, it has been consistently
demonstrated that the relative risk of death between PD and
HD varies by age and by primary cause of ESRD (diabetic
vs. non-diabetic causes) (4, 12-14). Similarly, patient age and
diabetes were key risk factors for death in this study.
We tried to evaluate the relative risk of death, adjusted and
stratified by the risk factors such as age and diabetes, was com-
pared among RRT group (Fig. 5). The time-dependent rel-
ative risk reflects an important and consistent trend across
various patient subgroups. In patients younger than 55 yr
irrespective of diabetes, the relative risk of PD was similar
or lower than that of HD for the first 24 months, but it be-
came higher than that of HD. This trend was remarkable
especially in diabetic patients older than 55 yr, though the
relative risk of PD was higher even at the early period. This
resultant trend was consistent with the previous mentioned
study by Vonesh et al. (25). The absence of early benefit of
PD in our study can be partially explained by our larger pro-
portion of diabetic patients than that in study by Vonesh et
al. Although we adjusted for several risk factors, it is possi-
ble that there was other unidentified yet important factor.
Further integrative evaluation containing those parameters
will be needed to find each effect on patient’s survival.
There are many logistic and ethical barriers to performing
a randomized trial to determine whether the treatments dif-
fer in patient outcome. Consequently, longitudinal epidemi-
ologic studies are necessary. The findings reported here should
be considered in the context of an observational study and
its inherent limitations. One concern regarding the internal
validity of this study is the presence of selection bias toward
one modality over another. We recognize that this study is
retrospective and extends over a long period time (from 1994
to 2004), and it may be argued that over these years many
changes in the practice of both HD and PD have occurred.
Thus, in this report, especially, evaluation of the clinical sig-
nificance of an association, examination of the likely causes
of an association, and careful review of potential sources of
bias are more important considerations than is the pvalue. 
In conclusion, the KT patients had the best survival rate,
and the HD patients had better survival than PD patients. The
consistent trend in different strata was as following: 1) The
risk of death for PD and HD was not proportional over time,
especially between HD and PD. 2) The relative risk of PD
was similar or lower than that of HD group for the first 12
months, but it became higher than that of HD at later peri-
od. The significant predictors of mortality were age (over 55
yr), presence of diabetes, cerebrovascular accident at the time
of RRT initiation, and more than one time of hospitalization
caused by malnutrition during follow-up. Further large-scaled,
multicenter-based comparative study is needed to reflect exact
characteristics and survival in Korean ESRD patients and
more meticulous attention is required in high-risk patients. 
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